文献速递心力衰竭与心肌病

司美格鲁肽对FLOW试验中糖尿病合并慢性肾脏病患者心力衰竭结局的影响

Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
PubMed 文献 · J Am Coll Cardiol · 2024-08-30

FLOW试验预设分析纳入3533例2型糖尿病合并慢性肾脏病患者,随机接受每周皮下司美格鲁肽1 mg或安慰剂,中位随访3.4年。司美格鲁肽降低首次心衰事件或心血管死亡复合终点风险(HR 0.73;95%CI 0.62-0.87;P=0.0005),且无论基线有无心衰,获益一致。

要点

  • 司美格鲁肽降低T2D合并CKD患者心衰事件或心血管死亡复合风险(HR 0.73)。
  • 单独心衰事件(HR 0.73)和心血管死亡(HR 0.71)风险均降低。
  • 基线有无心衰病史者获益一致,NYHA III级和HFrEF亚型风险总体更高。

核心结论

  • 在T2D合并CKD高危人群中,司美格鲁肽显著降低首次心衰事件或心血管死亡复合终点、心衰事件及心血管死亡风险。
  • 上述获益在基线有无心衰病史者中一致。

研究设计与样本

  • FLOW试验预设分析,参与者1:1随机接受每周皮下司美格鲁肽1 mg或安慰剂。
  • 共3533例随机参与者,中位随访3.4年。
  • 心衰数据由研究者收集,心血管死亡由独立委员会裁定。

主要发现

  • 总体人群中,司美格鲁肽延长至首次心衰事件或心血管死亡时间(HR 0.73;95%CI 0.62-0.87;P=0.0005)。
  • 心衰事件单独分析HR 0.73(95%CI 0.58-0.92;P=0.0068)。
  • 心血管死亡单独分析HR 0.71(95%CI 0.56-0.89;P=0.0036)。
  • 基线有心衰者复合心衰结局HR 0.73(95%CI 0.54-0.98;P=0.0338),无心衰者HR 0.72(95%CI 0.58-0.89;P=0.0028)。
  • NYHA III级和HFrEF亚型患者心衰结局风险总体更高,与治疗无关。

临床怎么用

  • 对于T2D合并CKD的高危患者,司美格鲁肽1 mg每周皮下注射可考虑用于降低心衰事件和心血管死亡风险。
  • 无论基线有无心衰病史,均可考虑使用司美格鲁肽以获取一致的心衰结局获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at high risk for heart failure (HF) and premature death from cardiovascular (CV) causes. The FLOW (Research Study To See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease), which enrolled participants with T2D and CKD, demonstrated that semaglutide, a glucagon-like peptide-1 receptor agonist, reduced the incidence of the primary composite outcome (persistent ≥50% decline in estimated glomerular filtration rate, persistent estimated glomerular filtration rate <15 mL/min/1.73 m2, kidney replacement therapy, and kidney or CV death) by 24%. OBJECTIVES: This prespecified analysis examined the effects of semaglutide on HF outcomes in this high-risk population. METHODS: Participants were randomized (1:1) to once-weekly subcutaneous semaglutide 1 mg or placebo. The prespecified main outcome was a composite of HF events (new onset or worsening of HF leading to an unscheduled hospital admission or an urgent visit, with initiation of or intensified diuretic/vasoactive therapy) or CV death. HF data were collected by the investigator. CV death was adjudicated by an independent committee. RESULTS: A total of 3,533 randomized participants were followed for a median of 3.4 years. HF was present at baseline in 342 participants (19.4%) in the semaglutide group and 336 (19.0%) in the placebo group. In the overall trial population, semaglutide increased time to first HF events or CV death (HR: 0.73; 95% CI: 0.62-0.87; P = 0.0005), HF events alone (HR: 0.73; 95% CI: 0.58-0.92; P = 0.0068), and CV death alone (HR: 0.71; 95% CI: 0.56-0.89; P = 0.0036). The risk reduction for the composite HF outcome was similar in those with (HR: 0.73; 95% CI: 0.54-0.98; P = 0.0338) and without (HR: 0.72; 95% CI: 0.58-0.89; P = 0.0028) HF at baseline. The risk of HF outcomes (HF events or CV death) was generally higher in participants categorized as NYHA functional class III and those with the HF reduced ejection fraction subtype, regardless of treatment. CONCLUSIONS: Semaglutide substantially reduced the risk of time to first composite outcome of HF events or CV death, as well as HF events and CV death alone, in a high-risk population with T2D and CKD. These effects were consistent regardless of history of HF. (A Research Study To See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease [FLOW]; NCT03819153).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Pratley, Tuttle, Rossing, et al. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. J Am Coll Cardiol. 2024. PMID: 39217553. doi:10.1016/j.jacc.2024.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。